ABBV: This Top Biotech Just Went On A Buying Spree
January 25, 2024 at 07:00 AM EST
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|